Zoetis (ZTS) Non-Current Deferred Tax Liability (2012 - 2026)
Zoetis' (ZTS) quarterly Non-Current Deferred Tax Liability came in at $130.0 million in Q1 2026, down 19.25% year-on-year from $161.0 million in Q1 2025, and down 5.11% on a QoQ basis from $137.0 million in Q4 2025.
Zoetis (ZTS) Non-Current Deferred Tax Liability (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Non-Current Deferred Tax Liability data on file, last reported at $130.0 million in Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 19.25% year-over-year to $130.0 million in Q1 2026; TTM through Mar 2026 was $130.0 million, a 19.25% decrease from a year earlier, with the FY2025 full-year figure at $137.0 million, down 17.96% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $130.0 million, down from $137.0 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for ZTS reached as high as $287.0 million in Q1 2022 and fell as low as $121.0 million in Q2 2023.
- Historically, Non-Current Deferred Tax Liability has averaged $170.5 million across 5 years, with a median of $156.0 million in 2025.
- Across the five-year window, Non-Current Deferred Tax Liability plunged 55.84% in 2023 and jumped 44.63% in 2024, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $142.0 million in 2022, then climbed by 2.82% to $146.0 million in 2023, then climbed by 14.38% to $167.0 million in 2024, then fell by 17.96% to $137.0 million in 2025, then retreated by 5.11% to $130.0 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $130.0 million in Q1 2026, $137.0 million in Q4 2025, and $147.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130.00 Mn |
| Mar 31, 2026 | 130.00 Mn |
| Dec 31, 2025 | 137.00 Mn |
| Dec 31, 2025 | 137.00 Mn |
| Sep 30, 2025 | 147.00 Mn |
| Sep 30, 2025 | 147.00 Mn |
| Jun 30, 2025 | 156.00 Mn |
| Jun 30, 2025 | 156.00 Mn |
| Mar 31, 2025 | 161.00 Mn |
| Mar 31, 2025 | 161.00 Mn |
| Dec 31, 2024 | 167.00 Mn |
| Dec 31, 2024 | 167.00 Mn |
| Sep 30, 2024 | 172.00 Mn |
| Sep 30, 2024 | 172.00 Mn |
| Jun 30, 2024 | 175.00 Mn |
| Jun 30, 2024 | 175.00 Mn |
| Mar 31, 2024 | 136.00 Mn |
| Mar 31, 2024 | 136.00 Mn |
| Dec 31, 2023 | 146.00 Mn |
| Dec 31, 2023 | 146.00 Mn |